ActoFactor™ Recombinant Human Vascular endothelial cell growth factor 145

Specification

Cat.No.

CSC-CTK0397

Description

A vascular endothelial growth factor (VEGF) mRNA species containing exons 1-6 and 8 of the VEGF gene was found to be expressed as a major VEGF mRNA form in several cell lines derived from carcinomas of the female reproductive system. This mRNA is predicted to encode a VEGF form of 145 amino acids (VEGF145). VEGF145 produced in insect cells is a homodimeric, 20,5 kDa protein belonging to the VEGFA family. Recombinant VEGF145 induced the proliferation of vascular endothelial cells and promoted angiogenesis in vivo. VEGF145 was compared with previously characterized VEGF species with respect to interaction with heparinlike molecules, cellular distribution, VEGF receptor recognition, and extracellular matrix (ECM) binding ability. VEGF145 shares with VEGF165 the ability to bind to the KDR/flk-1 receptor of endothelial cells. It also binds to heparin with an affinity similar to that of VEGF165. However, VEGF145 does not bind to two additional endothelial cell surface receptors that are recognized by VEGF165 but not by VEGF121. VEGF145 is secreted from producing cells as are VEGF121 and VEGF165. However, VEGF121 and VEGF165 do not bind to the ECM produced by corneal endothelial cells, whereas VEGF145 binds efficiently to this ECM. Basic fibroblast growth factor (bFGF)-depleted ECM containing bound VEGF145 induces proliferation of endothelial cells, indicating that the bound VEGF145 is active. The mechanism by which VEGF145 binds to the ECM differs from that of bFGF. Digestion of the ECM by heparinase inhibited the binding of bFGF to the ECM and released prebound bFGF, whereas the binding of VEGF145 was not affected by heparinase digestion. It therefore seems that VEGF145 possesses a unique combination of biological properties distinct from those of previously characterized VEGF species. The other members of this increasing growth factor family are VEGF-B, -C, -D and -E. Another member is the Placenta growth factor PlGF.

Species

Human

Product Overview

Human VEGFA expressed in Insect cells

Molecular Mass

32 kDa

Size

CAT# CSC-CTK0397-5 (5 μg); CAT# CSC-CTK0397-25 (25 μg)

Expression System

Insect cells

Purity

Greater than 95% as determined by SDS-PAGE analysis.

Activity

The ED50 for stimulation of 3H-thymidine incorporation and cell proliferation by human umbilical vein endothelial cells (HUVEC) for VEGF-145 has been determined to be in the range of 2-10 ng/ml.

Endotoxin Level

Less than 1 EU/μg.

Formulation

Lyophilized from a steril-filtered protein solution in 50 mM acetic acid with no additives.

Reconstitution

Please centrifuge product briefly before opening vial. The lyophilized protein should be reconstituted in sterile, ultra-pure water, PBS or medium to a concentration of 0.1 - 1.0 mg/ml. This solution can then be diluted into other aqueous buffers and stored at -20°C for future use.

Storage & Stability

The lyophilized protein, though stable at room temperature for up to 3 weeks, is best stored desiccated at -20°C. Reconstituted rHu VEGF-145 should be used immediately or stored long- term in undiluted working aliquots at -20°C. Avoid repeated freeze-thaw cycles.

Citation Guidance

If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

For research use only. Not for any other purpose.

Q & A
Customer Review

Ask a Question

Write your own review

ONLINE INQUIRY